

**MCLEOD & MOYNE, P.C.**  
**ATTORNEYS AND COUNSELORS AT LAW**  
**PATENTS, TRADEMARKS AND COPYRIGHTS**

IAN C. MCLEOD  
MARY M. MOYNE

2790 COMMONS PARKWAY  
OKEMOS, MICHIGAN 48864  
TELEPHONE (517) 347-4100  
FACSIMILE (517) 347-4103

TELEFAX TRANSMITTAL

To : Examiner S. Turner  
FIRM : PTO Group 164# 1644  
FAX NO. : 1-703-308-4426  
FROM : Ian C. McLeod  
DATE : 5/19/00 PAGES: (including cover sheet)

Re: application of Alberto L. Mendoza  
Serial No.: 09/082,112  
Filed : May 20, 1998  
Attorney Docket No. MSU 4.1-406

*Draft for Interview*

If transmission is interrupted or of poor quality, please notify us immediately by calling (517) 347-4100.

Notice: This communication is intended only for the use of the individual or entity to which it is addressed and may contain information that is privileged, confidential, and exempt from disclosure under applicable law. If the recipient of this communication is not the intended recipient or the employee or agent responsible for delivering the communication to the intended recipient, you are hereby notified that any dissemination, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please notify us immediately by telephone and return the communication to us at the above address via first class mail.

**MCLEOD & MOYNE, P.C.**  
ATTORNEYS AND COUNSELORS AT LAW  
PATENTS, TRADEMARKS AND COPYRIGHTS

IAN C. MCLEOD  
MARY M. MOYNE

2000 May 19

2190 CEDARHURST PARKWAY  
OKEMOS, MICHIGAN 48864  
TELEPHONE (517) 347-4100  
FACSIMILE (517) 347-4103

Examiner S. Turner  
PTO Group 1645

Re: application of Alberto L. Mendoza  
Serial No.: 09/082,112  
Filed: May 20, 1998  
For: METHOD AND VACCINE FOR TREATMENT OF  
PYTHIOSIS INSIDIOSI IN HUMANS AND  
LOWER ANIMALS

Attorney Docket No.: MSU 4.1-406


Dear Ms. Turner:

In preparation for the interview which you suggested, enclosed are possible modifications to the claims which should clarify them. You can telephone me after you have reviewed them.

If there are any questions, please let me know.

Best wishes.

Sincerely,



Ian C. McLeod  
ICM/ejm  
encl.

MSU 4.1-406

S.N. 09/082,112

Claim modifications for consideration by Examiner

-16- (Twice Amended)

1                   A method for treatment of Pythiosis in human  
2 patients having the disease which comprises:

3                   (a) providing a vaccine containing a mixture  
4 of proteins of *Pythium insidiosum* in a sterile aqueous  
5 solution, wherein the mixture of proteins is (1) of  
6 mixed intracellular proteins separately removed from  
7 disrupted cells of the *Pythium insidiosum* grown in a  
8 culture medium and (2) of mixed extracellular proteins  
9 separately removed from the culture medium for growing  
10 the *Pythium insidiosum*, and then (1) and (2) were mixed  
11 together; and

12                   (b) vaccinating the patient with the vaccine.

-2-

-18- (Twice amended)

1 A method for the treatment of Pythiosis in a  
2 mammal having the disease which comprises:

3 (a) providing an injectable vaccine derived  
4 from growing cells of *Pythium insidiosum* in a culture  
5 medium which comprises in a sterile aqueous solution in  
6 admixture:

7 (1) mixed intracellular proteins separately  
8 removed from disrupted cells of the *Pythium insidiosum*;  
9 and

10 (2) mixed extracellular proteins separately  
11 removed from a supernatant from growing the cells of the  
12 *Pythium insidiosum*, wherein the separately removed (1)  
13 and (2) were mixed together; and

14 (b) vaccinating the mammal with the vaccine.

-3-

-19- (Twice Amended)

1           The method of Claim 18 wherein the  
2   intracellular and extracellular [removed] proteins have  
3   been provided by growing cells of the *Pythium insidiosum*  
4   in the culture medium, then killing the cells, then  
5   separating the killed cells from the culture medium to  
6   produce a first supernatant containing the mixed  
7   extracellular proteins and then disrupting the killed  
8   cells in sterile water to provide the mixed  
9   intracellular proteins in a second supernatant and  
10   separately removing the mixed intracellular proteins  
11   from the disrupted cells and separately removing the  
12   mixed extracellular proteins [from the disrupted cells  
13   and removing mixed extracellular proteins] from the  
14   first supernatant, and mixing the separately removed  
15   extracellular proteins and intracellular proteins  
16   together.